{"type":"trials","record":{"id":34743,"source_id":"clinicaltrials-gov","external_id":"NCT07004595","title":"Evaluation of Frailty in Patients With Fibrosing Interstitial Lung Diseases: Prognostic and Therapeutic Impact","brief_summary":"Fibrosing interstitial lung diseases (ILDs), with idiopathic pulmonary fibrosis being the most common form, primarily affect older individuals and have a poor prognosis, with a median survival of 3 to 5 years. While antifibrotic treatments such as nintedanib and pirfenidone can slow disease progression, their efficacy is often limited by side effects, particularly in elderly patients. A comprehensive patient assessment, including evaluations of frailty and sarcopenia, could optimize care by identifying those at risk for poor outcomes or poor treatment tolerance. Frailty, characterized by reduced physiological reserves, and sarcopenia, defined as a loss of muscle mass and strength, are both associated with increased mortality and morbidity risks. Although their individual impacts on fibrosing ILDs have been documented, the combined effect of these two syndromes on patient prognosis remains unexplored, highlighting the need for further studies to guide therapeutic decision-making.","overall_status":"Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Nantes University Hospital","enrollment":100,"countries":["France"],"start_date":"2025-07-20","completion_date":"2027-12-20","last_update_date":"2026-06-24","source_url":"https://clinicaltrials.gov/study/NCT07004595","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:20:20.087268+00:00","last_seen_at":"2026-09-25T06:15:20.281+00:00","metadata":{"sex":"ALL","acronym":"FRAPID","age_range":"65 Years","comparator":null,"organization":"Nantes University Hospital","interventions":["Evaluation of patient frailty"],"registry_source":"ClinicalTrials.gov","outcome_measures":["to analyze the prognostic value of the phenotypes \"frail and sarcopenic,\" \"frail only,\" \"sarcopenic only,\" and \"robust\"…","to analyze the progression of sarcopenia — up to 12 months"],"design_description":null,"source_has_results":false},"controlled_terms":["Sarcopenia","Evaluation of patient frailty"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: frailty.","quality_checked_at":"2026-09-25T06:15:30.843286+00:00","duplicate_cluster_key":"id:nct07004595","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-07-20 to 2027-12-20","comparator":null,"confidence":"structured-source","population":"ALL · 65 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:15:20.306Z","intervention":["Evaluation of patient frailty"],"participants":100,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["to analyze the prognostic value of the phenotypes \"frail and sarcopenic,\" \"frail only,\" \"sarcopenic only,\" and \"robust\"…","to analyze the progression of sarcopenia — up to 12 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"frailty","is_published":true,"match_reasons":["Title contains controlled term: frailty.","Abstract contains controlled term: frailty.","Source terminology contains: frailty.","Title supplies longevity context: frailty, frail.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Frailty","slug":"frailty"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/34743","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}